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ABSTRACT
Background: Periostin, an extracellular matrix protein, is involved in inflammatory processes 
of the lung. To date, most studies have focused on periostin in asthma patients, its role in chron-
ic obstructive pulmonary disease (COPD) is less clear and no information has been reported 
on blood levels of periostin in COPD patients in the context of exacerbation rates. As such, 
this exploratory study aimed to investigate whether periostin is helpful to distinguish between 
COPD patients with frequent and infrequent exacerbations.
Methods: We performed an examination of patients with COPD participating in a COPD cohort 
study in Switzerland. Periostin levels were determined in serum samples by using a commer-
cially available enzyme-linked immunosorbent assay (ELISA) kit. Patients underwent eval-
uation of clinical symptoms including exacerbation rate (exacerbation defined by requiring 
oral corticosteroids and/or antibiotics) and lung function. In a subgroup of patients an annual 
follow-up was available that was considered in an additional analysis.
Results: Twenty six patients (global initiative of obstructive lung disease (GOLD) stage 1 none, 
31% stage 2, 38% stage 3, 31% stage 4) were included in the analysis. The mean±standard 
deviation (SD) age of the patients was 63±5.9 years, 16 were males, 24 were smokers or ex-
smokers. The median (quartiles) post-bronchodilator FEV
1
% predicted was 36(27/57). There 
was no significant difference in periostin levels between patients with frequent and infrequent 
exacerbations. The follow-up data revealed no evidence that periostin is helpful in distinguish-
ing frequent from infrequent exacerbators.
Conclusion: Our analysis performed in a small group of carefully matched COPD patients 
demonstrates that there is no significant relationship between exacerbation rate and periostin 
levels in blood.
KEYWORDS: COPD; Periostin; Eosinophilic inflamation; Exacerbations. 
ABBREVIATIONS: BMI: Body Mass Index; COPD: Chronic Obstructive Pulmonary Disease; 
ELISA: Enzyme-Linked Immunosorbent Assay; FEV
1
: Forced expiratory volume in one sec-
ond; GOLD: Global Initiative of Obstructive Lung Disease; SD: Standard Deviation; WIS-
DOM: Withdrawal of Inhaled Steroids during Optimised bronchodilator Management; QoL: 
Quality of Life; CGPS: Copenhagen General Population Study.
Trial Registration: https://clinicaltrials.gov/, NCT01527773. Registered 18.01.2012 (retrospec-
tively registered).
To the Editor,
Periostin, a multifunctional matricelluar protein, has been reported to be an excellent predictor 
of airway eosinophilia.1 Eosinophilic inflammation within the airways is usually considered as 
a hallmark of patients with asthma and it was found that the exacerbation rate was significantly 
reduced in patients with high levels of periostin.2 While, to date, most studies have focused on 
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periostin in asthma, its role in COPD is less clear and no infor-
mation has been reported on blood levels of periostin in COPD 
patients in the context of exacerbation rates. However, recent 
publications focused on the important role of eosinophils and 
their association with exacerbation rate.3,4 Moreover, COPD pa-
tients with elevated eosinophil counts also had an increased risk 
of exacerbations.5 A recent publication implied that high blood 
eosinophils and high plasma periostin were associated with im-
proved lung function three months after starting treatment with 
inhaled corticosteroids in combination with a long acting bron-
chodilator.5
 These data suggest that periostin may serve as a bio-
marker in COPD patients. As such, this exploratory study aimed 
to gain insight whether periostin is helpful to distinguish be-
tween COPD patients with frequent and infrequent exacerba-
tions.
 We performed an examination of patients with COPD 
participating in a COPD cohort study from seven pulmonary 
clinics in Switzerland (NCT01527773). The cantonal ethics 
committee of Zurich approved the study and patients provided 
written informed consent (KEK-ZH-Nr. 2011-0106). Perios-
tin levels were determined in serum samples by using a com-
mercially available ELISA kit (Thermo Fisher Scientific, Zug, 
Switzerland). COPD severity was defined according to GOLD 
guidelines. Patients underwent evaluation of clinical symptoms 
including exacerbation rate (exacerbation defined by requiring 
oral corticosteroids and/or antibiotics) and lung function. All pa-
tients were examined in a stable phase of the disease and, in case 
of an acute exacerbation, the evaluation was postponed by at 
least 6 weeks.
 Comparisons among groups were performed with 
paired t-test, Wilcoxon signed ranks test and chi-square test.
 Since the number of patients with frequent exacerba-
tions (≥2 per year) was considerably lower than the number of 
patients with infrequent exacerbations, we matched every pa-
tient from the frequent exacerbator group to a patient with infre-
quent exacerbations. Matching criteria included age, body mass 
index (BMI) and disease severity according to FEV
1
. Smoking 
was considered as additional confounder in the analysis because 
it has been reported recently that periostin may be repressed by 
smoking.6
 Twenty six patients (GOLD stage 1 none, 31% stage 
2, 38% stage 3, 31% stage 4) were included in the analysis. The 
mean±SD age of the patients was 63±5.9 years, 16 were males, 
24 were smokers or ex-smokers. The median (quartiles) post-
bronchodilator FEV
1
% predicted was 36(27/57). There was no 
significant difference among the two groups for demographic 
data. In a subgroup of patients an annual follow-up was avail-
able that was considered in an additional analysis.
 When COPD patients with frequent exacerbations were 
compared to their matched peers with infrequent exacerbations, 
no signifcant difference in periostin blood levels was detected. 
Since in a subgroup of patients annual measurements were avail-
able, we also analyzed patients that changed their exacerbation 
frequency over time, e.g. from frequent to infrequent or vice ver-
sa. This additional analysis provided no evidence to support that 
periostin is helpful in segregating both groups. No correlation 
was found between the level of serum eosinophils and periostin 
in our cohort (Table 1).
 Frequent exacerbations, predominantly found in pa-
tients with severe COPD, result in accelerated disease progres-
sion and mortality.7 These patients usually have a more rapid de-
cline in lung function, worse quality of life (QoL) and decreased 
exercise performance. In a stepwise regression performed in 
more than 2000 COPD patients the history of previous exac-
erbations was found to be the strongest predictor of subsequent 
COPD exacerbations.8
 In addition, a number of previous studies were under-
taken to identify biomarkers that may help to predict exacerba-
tion frequency.9 To date, however, no serum biomarkers reliably 
predict exacerbation frequency in COPD patients.
 Blood eosinophils in COPD have been shown to pre-
dict corticosteroid responsiveness during acute exacerbation. 
Patients with a peripheral blood eosinophil count of ≥2% at the 
onset of an outpatient managed exacerbation responded prompt-
ly to prednisolone, whereas those with a count of <2% had a 
higher rate of treatment failure compared with placebo.10 In a 
post-hoc analysis of the withdrawal of inhaled steroids during 
optimised bronchodilator management (WISDOM)-trial Watz 
and colleagues4 demonstrated that withdrawal of inhaled corti-
costeroids in COPD patients with an elevated baseline serum 
eosinophil count led to a higher risk of moderate to severe exac-
erbations. The authors concluded that an eosinophil count of 4% 
or greater 300 cells per µl may predispose to a deleterious effect 
of inhaled corticosteroid withdrawal.4 A recent analysis of the 
data from the Copenhagen General Population Study (CGPS) 
revealed that in COPD patients an increased blood eosinophil 
level above 0.34 (gram/liter) g/l was associated with a 1.76-fold 
increased risk of severe exacerbations.3
 While these publications highlight the role of eosino-
phils in COPD, in particular in the context of acute exacerba-
tions, to the best of our knowledge our study is the first report on 
the levels of periostin in COPD and exacerbation rate.
 The current analysis focusing on the role of periostinin 
stable patients with COPD however did not help to stratify pa-
tients into frequent or infrequent exacerbators.
 Smoking was recently postulated to repress periostin 
at the individual gene level.6 However, in our study only 1 pa-
tient in the infrequent exacerbation group and two patients of the 
frequent exacerbators were active smokers and the association 
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between smoking status and periostin level was not significant. 
Moreover, recent findings from a large cross-sectional study sug-
gested that serum levels of periostin do not have to be adjusted 
for smoking history, age and gender.11 As such, it is unlikely that 
the levels of periostin in our cohort have been under estimated.
 In summary, our observation, although limited by the 
small size, suggests that serum periostin levels do not help dis-
tinguishing COPD patients with frequent from those with in-
frequent exacerbations. Future studies will have to determine 
whether periostin levels are useful in guiding therapeutic strate-
gies in patients with COPD as it has been demonstrated in asth-
ma patients.
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